|
Nov 11
|
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
|
|
Jul 29
|
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
|
|
Jul 23
|
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
|
|
May 23
|
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 8
|
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
|
|
May 3
|
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
|
|
May 3
|
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
|
May 2
|
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
|
|
Apr 24
|
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 18
|
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
|
|
Mar 4
|
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
|
|
Dec 21
|
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 8
|
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Dec 5
|
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
|
|
Dec 4
|
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Nov 29
|
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
|
|
Nov 28
|
SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer Treatment
|
|
Nov 27
|
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
|
|
Nov 2
|
SpringWorks Therapeutics Inc (SWTX) Reports Q3 2023 Financial Results
|
|
Nov 2
|
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
|